The Clinical Significance of SPOP Upregulation and Nuclear Accumulation in Head and Neck Squamous Cell Carcinoma
International Journal of Molecular Sciences · 28.02.2026 · 27 (5) · 2285
DOI: 10.3390/ijms27052285 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2026. Verfasst von Yin-Hwa Shih und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan. Hauptthemen laut MEDLINE: Repressor Proteins, Nuclear Proteins, Cell Nucleus, Up-Regulation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University, National Science and Technology Council, Changhua Christian Hospital.
Abstract (Originalsprache)
The speckle-type BTB/POZ protein (SPOP) is an E3 ubiquitin ligase adaptor typically considered a tumor suppressor, yet its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study investigated SPOP expression, arecoline regulation, and its potential as a HNSCC biomarker. SPOP mRNA and its protein were quantified in HNSCC (FaDu, GMN, HSC-3, SAS, and A253) and normal oral epithelial (SG) cell lines via RT-qPCR and Western blot; arecoline’s effect on SG, SAS, and A253 cells was evaluated. SPOP mRNA was analyzed using The Cancer Genome Atlas (TCGA) HNSCC cohort, and protein localization was assessed via immunohistochemistry (IHC) on tissue microarrays. SPOP mRNA was higher in some HNSCC lines; arecoline induced SPOP in SG cells, but not in HNSCC cell lines. TCGA confirmed SPOP mRNA upregulation in tumors correlating with grade. IHC showed SPOP upregulation in HNSCC, particularly in palate and pharynx/hypopharynx sites. The nuclear SPOP-positive ratio shifted from 12.14 ± 9.82% in normal tissues to 61.26 ± 33.03% in tumors (p < 0.0001), differentiating grades and sites better than total expression. SPOP is upregulated in HNSCC and inducible by arecoline. Enhanced nuclear SPOP localization indicates malignancy and progression, identifying it as a potential HNSCC diagnostic and progression biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan.
- Department of Oral and Maxillofacial Surgery, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
- School of Dentistry, China Medical University, Taichung 404328, Taiwan.
- Department of Dentistry, China Medical University Hospital, Taichung 40447, Taiwan.
- Tissue Bank, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan.
- Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
ORCID-Profile: Yin-Hwa Shih, Nan-Chin Lin, Tong-Hong Wang, Yu-Hsin Tseng, Shih-Min Hsia, Tzong-Ming Shieh
Förderung
- China Medical University
- National Science and Technology Council
- Changhua Christian Hospital
Zitieren
APA
Shih, Y. H., Lin, N. C., Shen, Y. W., Tu, M. G., Wang, T. H., Tseng, Y. H., Hsia, S. M., & Shieh, T. M. (2026). The Clinical Significance of SPOP Upregulation and Nuclear Accumulation in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 27(5), 2285. https://doi.org/10.3390/ijms27052285
Vancouver
Shih YH, Lin NC, Shen YW, Tu MG, Wang TH, Tseng YH, et al. The Clinical Significance of SPOP Upregulation and Nuclear Accumulation in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2026;27(5):2285. doi:10.3390/ijms27052285
BibTeX
@article{Shih2026,
author = {Shih, Yin-Hwa and Lin, Nan-Chin and Shen, Yen-Wen and Tu, Ming-Gene and Wang, Tong-Hong and Tseng, Yu-Hsin and Hsia, Shih-Min and Shieh, Tzong-Ming},
title = {The Clinical Significance of SPOP Upregulation and Nuclear Accumulation in Head and Neck Squamous Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2285},
doi = {10.3390/ijms27052285}
}
EUVIMED